Elan Corporation PLC and Biogen Idec, Inc. (Massachusetts) Announce a FDA Advisory Committee Meeting to Review TYSABRI(R) for the Treatment of Crohn’s Disease

CAMBRIDGE, Mass. & DUBLIN, Ireland--(BUSINESS WIRE)--Elan Corporation, plc. (NYSE: ELN) and Biogen Idec (NASDAQ: BIIB) announced today that the Gastrointestinal Drugs Advisory Committee and Drug Safety and Risk Management Advisory Committee of the U.S. Food and Drug Administration (FDA) will jointly review TYSABRI® (natalizumab) for the treatment of Crohn’s disease (CD) on July 31, 2007.